Danaher Co. (NYSE:DHR) Shares Sold by Folger Nolan Fleming Douglas Capital Management Inc.

Folger Nolan Fleming Douglas Capital Management Inc. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 3.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,911 shares of the conglomerate’s stock after selling 130 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Danaher were worth $905,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. BKM Wealth Management LLC acquired a new stake in shares of Danaher in the fourth quarter valued at $27,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at $29,000. OFI Invest Asset Management acquired a new stake in shares of Danaher in the third quarter valued at $30,000. Rakuten Securities Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at $36,000. Finally, GHP Investment Advisors Inc. raised its stake in shares of Danaher by 540.0% in the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock valued at $40,000 after acquiring an additional 135 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DHR has been the topic of several analyst reports. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Barclays raised their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. Raymond James raised their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. TD Cowen raised their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $270.00.

Danaher Stock Performance

DHR traded up $0.78 during trading on Friday, reaching $246.58. The company’s stock had a trading volume of 2,710,446 shares, compared to its average volume of 2,710,897. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00. The company’s fifty day moving average price is $248.87 and its 200-day moving average price is $231.08. The company has a market capitalization of $182.64 billion, a price-to-earnings ratio of 41.77, a price-to-earnings-growth ratio of 3.78 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the firm earned $2.36 EPS. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, equities analysts forecast that Danaher Co. will post 7.65 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date was Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders sold 106,565 shares of company stock worth $26,641,364 in the last ninety days. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.